NGEN NERVGEN PHARMA CORP.
Price Chart
Executive Summary
NervGen Pharma priced an underwritten public offering of 24,000,000 common shares and accompanying warrants at $2.50 per unit, raising approximately $60 million in gross proceeds. The proceeds will fund clinical studies of NVG-291 and general corporate purposes. Insider PFP Biosciences participated, increasing its stake but seeing its ownership percentage drop from 17.87% to 14.58% due to dilution.
Actionable Insight
The $60M offering at a 35% discount to the warrant exercise price ($3.68) signals near-term capital needs and dilutes existing holders by ~29%. Monitor for clinical data readouts on NVG-291 as the primary catalyst; the cash runway extension is positive but the dilution overhang is material. Historical calibration shows score-6 filings on this ticker have a 31% probability of positive T+20 alpha with a net negative average alpha of -2.75% in this segment, suggesting limited upside from the offering news alone.
Key Facts
- Offering of 24,000,000 common shares and warrants at $2.50 per unit
- Gross proceeds of approximately $60.0 million
- Warrants exercisable at $3.68 per share, immediately exercisable, 5-year term
- Insider PFP Biosciences participated; its ownership fell from 17.87% to 14.58% post-offering
- Proceeds to advance NVG-291 clinical studies and for working capital
- Leerink Partners and TD Securities acted as joint bookrunning managers
Financial Impact
Dilutive offering of $60M gross proceeds at $2.50/share, representing ~29% of pre-offering market cap ($170M). Warrants add further potential dilution of up to 24M shares at $3.68.
Risk Factors
- Significant dilution: 24M new shares + 24M warrants could increase share count by up to 48M, more than doubling current outstanding shares
- Warrant overhang at $3.68 may cap upside until exercised or expired
- Clinical-stage biotech with no approved products; NVG-291 development risk remains high
- Insider participation does not fully offset dilution signal
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-069028 |
| Document: tm2616544d1_6k.htm | 0001104659-26-069028 |
| Document: 0001104659-26-069028-index-headers.html | 0001104659-26-069028 |
| Document: 0001104659-26-069028-index.html | 0001104659-26-069028 |
| Document: 0001104659-26-069028.txt | 0001104659-26-069028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
13d ago
|
6-K
| $2.00 $1.91 | ▲ +4.50% | ▲ +3.78% | $1.92 (+4.00%) |
|
May 27, 2026
19d ago
|
EFFECT
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.07% | $1.92 (−7.25%) |
|
May 26, 2026
19d ago
|
6-K
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.06% | $1.92 (−7.25%) |
|
May 22, 2026
23d ago
|
6-K
| $2.13 $2.07 | ▲ +2.82% | ▲ +2.83% | $1.92 (+9.86%) |
|
May 22, 2026
24d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 21, 2026
24d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 18, 2026
27d ago
|
6-K
| $3.56 $3.74 | ▲ +5.06% | ▲ +4.02% | $1.92 (−46.07%) |
|
May 18, 2026
27d ago
|
Press Release
| $3.64 $3.56 | ▲ +2.20% | ▲ +1.55% | $1.92 (+47.25%) |
|
Apr 27, 2026
6w ago
|
6-K
| $3.88 $3.75 | ▼ −3.41% | ▼ −3.40% | $1.92 (−50.52%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $3.77 $4.36 | ▲ +15.65% | ▲ +14.90% | $1.92 (−49.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access